Aclaris Therapeutics (ACRS) Shares Sold by Metropolitan Life Insurance Co. NY
Metropolitan Life Insurance Co. NY decreased its position in Aclaris Therapeutics (NASDAQ:ACRS) by 48.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 7,467 shares of the biotechnology company’s stock after selling 6,907 shares during the period. Metropolitan Life Insurance Co. NY’s holdings in Aclaris Therapeutics were worth $184,000 as of its most recent SEC filing.
A number of other institutional investors have also recently bought and sold shares of ACRS. Cubist Systematic Strategies LLC purchased a new position in Aclaris Therapeutics in the third quarter valued at approximately $142,000. Teacher Retirement System of Texas purchased a new position in Aclaris Therapeutics in the fourth quarter valued at approximately $200,000. Millennium Management LLC purchased a new position in Aclaris Therapeutics in the fourth quarter valued at approximately $291,000. Landscape Capital Management L.L.C. purchased a new stake in shares of Aclaris Therapeutics during the fourth quarter worth $307,000. Finally, Caxton Corp lifted its position in shares of Aclaris Therapeutics by 76.8% during the fourth quarter. Caxton Corp now owns 17,994 shares of the biotechnology company’s stock worth $444,000 after acquiring an additional 7,818 shares in the last quarter. Institutional investors and hedge funds own 92.32% of the company’s stock.
Several equities research analysts have issued reports on the company. Cantor Fitzgerald restated a “buy” rating and set a $50.00 target price on shares of Aclaris Therapeutics in a research report on Monday, March 12th. Leerink Swann dropped their target price on Aclaris Therapeutics from $56.00 to $54.00 and set an “outperform” rating on the stock in a research report on Tuesday, March 13th. BidaskClub downgraded Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, January 18th. Finally, Zacks Investment Research downgraded Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, January 3rd. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the stock. Aclaris Therapeutics presently has an average rating of “Hold” and an average target price of $43.50.
NASDAQ:ACRS opened at $18.08 on Friday. The firm has a market cap of $547.88, a price-to-earnings ratio of -7.23 and a beta of 1.63. Aclaris Therapeutics has a 1 year low of $16.01 and a 1 year high of $30.08.
Aclaris Therapeutics (NASDAQ:ACRS) last posted its earnings results on Monday, March 12th. The biotechnology company reported ($0.80) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.90) by $0.10. The company had revenue of $1.00 million for the quarter, compared to analysts’ expectations of $0.80 million. sell-side analysts forecast that Aclaris Therapeutics will post -4.27 EPS for the current year.
About Aclaris Therapeutics
Aclaris Therapeutics, Inc, a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies to address the unmet needs in medical and aesthetic dermatology and immunology in the United States. The company operates in two segments, Dermatology Therapeutics and Contract Research.
Want to see what other hedge funds are holding ACRS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aclaris Therapeutics (NASDAQ:ACRS).
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.